Compare Becton Dickinson and Co (BDX) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Manhattan Associates Inc — how do they compare? Becton Dickinson and Co trades at $149.95 (market cap $41.51B), while Manhattan Associates Inc trades at $159.96 (market cap $9.38B). The key difference: Becton Dickinson and Co is far larger — about 4.4× Manhattan Associates Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| BDX | MANH | |
|---|---|---|
Market Cap | $41.51B | $9.38B |
Sector | Health | Technology |
52-Week High | $185.39 | $227.94 |
52-Week Low | $135.49 | $120.88 |
Enterprise Value | $57.97B | $9.21B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
MANH trades at $158.31, up 2.2% today, with a bullish technical outlook supported by moving averages and strong quarterly EPS beats. The company maintains robust profitability with a 19.68% net margin and 96.24% ROE, though valuation multiples like P/E of 44.43 are elevated. Recent news highlights ongoing legal investigations but also cloud growth initiatives.
Outlook remains positive with a $192.80 analyst price target implying 22% upside, but risks include high valuation sensitivity, legal overhang from fiduciary investigations, and competitive pressures in supply chain software. Earnings momentum and institutional support provide near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
